Related Experiment Video
Updated: Oct 28, 2025

11:26
Sequencing of mRNA from Whole Blood using Nanopore Sequencing
Published on: June 3, 2019
14.0K
Nanopanel2 calls phased low-frequency variants in Nanopore panel sequencing data
Niko Popitsch1,2, Sandra Preuner1, Thomas Lion1,3
1Children's Cancer Research Institute, Vienna 1090, Austria.
Bioinformatics (Oxford, England)
|July 16, 2021
Summary
Nanopanel2 is a new variant caller for Nanopore sequencing data that enables accurate haplotype phasing and somatic variant detection. This tool provides fast and cost-effective diagnostic workflows for genomic analysis.
Area of Science:
- Genomics and Bioinformatics
- Molecular Diagnostics
Background:
- Clinical decision-making relies on accurate detection of somatic variants and their haplotypes.
- Short-read sequencing has limitations in haplotype phasing due to read length, hindering detection of co-occurring variants.
- Long-read sequencing offers direct phasing but has been limited by high error rates.
Purpose of the Study:
- To develop a robust variant caller for Nanopore panel sequencing data.
- To enable accurate haplotype calling and somatic variant detection using long-read sequencing.
- To establish a fast, accurate, and cost-effective diagnostic workflow.
Main Methods:
- Developed Nanopanel2, a variant caller operating directly on base-called FAST5 files.
- Utilized allele probability distributions and filters to distinguish true variants from false positives.
- Enabled direct phasing of variants on the same read for haplotype determination.
Main Results:
- Nanopanel2 accurately calls single nucleotide variants (SNVs) and insertions/deletions (INDELs) down to 1% and 5% variant allele frequency, respectively.
- The caller produces minimal low-frequency false positives (approximately 1 FP call with VAF<5% per kb amplicon).
- Achieved direct phasing of amplicon variants, overcoming limitations of short-read sequencing.
Conclusions:
- Nanopanel2 is the first somatic variant caller designed for Nanopore sequencing data.
- Enables accurate, rapid (under 48 hours), and affordable (approx. $10/sample) diagnostic workflows.
- Facilitates improved clinical decision-making through direct haplotype phasing and sensitive variant detection.

